Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a 72-Hour drug course save more lives after cardiac arrest?

NCT ID NCT06835491

Disease control Sponsor: Versailles Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving the heart medication amiodarone for 72 hours can reduce death and prevent life-threatening heart rhythms in critically ill patients who survived a cardiac arrest with a shockable rhythm. About 674 adults in intensive care will receive either amiodarone or a placebo. The goal is to see if this short-term treatment improves survival and reduces dangerous heart events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 674 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient aged ≥ 18 years 2. Admitted in intensive care unit 3. Out-of-hospital cardiac arrest with initial shockable rhythm 4. Presumed cardiac or unknown cause 5. Delay between ROSC and screening for randomisation \< 6 hours 6. Informed consent from the patient or a surrogate or deferred consent 7. Affiliated to or benefiting from a social insurance Exclusion Criteria: 1. Cardiac arrest secondary to an extra-cardiac cause (suspected or confirmed) 2. Indication for amiodarone decided by the physician at ICU admission 3. No central venous catheter available for continuous infusion of amidoarone 4. Thyroid disease under treatment 5. History of cardiac conduction disorders, not treated by permanent pacemaker 6. Any contra indication to amiodarone treatment 7. Refractory ventricular arrhythmia or electrical storm 8. Need for veno-arterial extracorporeal membrane oxygenation (VA-ECMO) at admission 9. Known limitations in therapy and Do Not Resuscitate-order 10. Moribund patient due to pre-arrest history (estimated life expectancy \< 3 months) 11. Pregnant or breastfeeding women 12. Patient needing a nadolol treatment due to QT long syndrome or catecholaminergic polymorphic ventricular tachycardia 13. Patient with known pulmonary fibrosis 14. Patient with known interstitial lung disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ventricular arrhythmias and cardiac arrest are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiac arrest

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ventricular arrhythmias and cardiac arrest

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    29 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ap Hm

    RECRUITING

    Marseille, France

  • CH Brive

    RECRUITING

    Brive-la-Gaillarde, France

  • CH Cotentin

    RECRUITING

    Valognes, France

  • CH Mondor

    RECRUITING

    Aurillac, France

  • CH annecy genevois

    RECRUITING

    Annecy, France

  • CH la rochelle

    RECRUITING

    La Rochelle, France

  • CHD vendée

    RECRUITING

    La Roche-sur-Yon, France

  • CHI Toulon

    RECRUITING

    Toulon, France

  • CHSF

    RECRUITING

    Corbeil-Essonnes, France

  • CHU Brest

    RECRUITING

    Brest, France

  • CHU Cochin

    RECRUITING

    Paris, France

  • CHU Nantes

    NOT_YET_RECRUITING

    Nantes, France

  • CHU Nice -MIR Archet

    RECRUITING

    Nice, France

  • CHU Nice -MIR Pasteur

    RECRUITING

    Nice, France

  • CHU Poitiers

    RECRUITING

    Poitiers, France

  • Ch Argenteuil

    RECRUITING

    Argenteuil, France

  • Chi Nord Ardennes

    RECRUITING

    Charleville-Mézières, France

  • Chu Amiens

    NOT_YET_RECRUITING

    Amiens, France

  • Chu Angers

    RECRUITING

    Angers, France

  • Chu Caen

    NOT_YET_RECRUITING

    Caen, France

  • Chu Orléans

    RECRUITING

    Orléans, France

  • Chu Strasbourg

    RECRUITING

    Strasbourg, France

  • Chu Toulouse

    RECRUITING

    Toulouse, France

  • Clinique Ambroise Paré

    RECRUITING

    Neuilly-sur-Seine, France

  • Hcl

    RECRUITING

    Lyon, France

  • Hopital Cartier

    RECRUITING

    Massy, France

  • Hopital saint joseph

    RECRUITING

    Paris, France

  • Hoptial Mulhouse

    RECRUITING

    Mulhouse, France

  • chi Gregoire

    NOT_YET_RECRUITING

    Montreuil, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.